Suzuki T, Tsuji M, Mori T, Misawa M, Nagase H
Department of Pharmacology, School of Pharmacy, Hoshi University, Tokyo, Japan.
Psychopharmacology (Berl). 1996 Apr;124(3):211-8. doi: 10.1007/BF02246659.
The effects of the dopamine D1 antagonist SCH23390 and the D2 antagonist sulpiride on the rewarding effects of delta opioid receptor agonists were examined in mice. Both [D-Pen2, Pen5]enkephalin (DPDPE, 1-15 nmol, ICV), a selective delta 1 opioid receptor agonist, and [D-Ala2]deltorphin II (DELT, 0.5-5 nmol, ICV), a selective delta 2 opioid receptor agonist, produced a dose-dependent place preference in mice. The DPDPE (15 nmol, ICV)-induced place preference was abolished by BNTX (0.5 mg/kg, SC), a delta 1 opioid receptor antagonist, but not by NTB (0.5 mg/kg, SC), a delta 2 opioid receptor antagonist. In contrast, the DELT (5 nmol, ICV)-induced place preference was antagonized by NTB, but not BNTX. Pretreatment with SCH23390 (3 micrograms/kg, SC) abolished the DPDPE-induced place preference, but not affect the DELT-induced place preference. Moreover, pretreatment with sulpiride (40 mg/kg, SC) did not modify the place preference induced by DPDPE or DELT. In the present study, we found that the activation of both central delta 1 and delta 2 opioid receptors produced rewarding effects. Furthermore, these results suggest that the rewarding effects of delta 1 opioid receptor agonist may be produced through activation of the central dopaminergic system, especially dopamine D1 receptors, whereas the rewarding effects of delta 2 opioid receptor agonists may be produced by some other mechanism(s).
在小鼠中研究了多巴胺D1拮抗剂SCH23390和D2拮抗剂舒必利对δ阿片受体激动剂奖赏效应的影响。选择性δ1阿片受体激动剂[D-青霉胺2,青霉胺5]脑啡肽(DPDPE,1 - 15 nmol,脑室内注射)和选择性δ2阿片受体激动剂[D-丙氨酸2]强啡肽II(DELT,0.5 - 5 nmol,脑室内注射)均可在小鼠中产生剂量依赖性位置偏爱。δ1阿片受体拮抗剂BNTX(0.5 mg/kg,皮下注射)可消除DPDPE(15 nmol,脑室内注射)诱导的位置偏爱,但δ2阿片受体拮抗剂NTB(0.5 mg/kg,皮下注射)则不能。相反,NTB可拮抗DELT(5 nmol,脑室内注射)诱导的位置偏爱,而BNTX则不能。用SCH23390(3微克/千克,皮下注射)预处理可消除DPDPE诱导的位置偏爱,但不影响DELT诱导的位置偏爱。此外,用舒必利(40 mg/kg,皮下注射)预处理不会改变DPDPE或DELT诱导的位置偏爱。在本研究中,我们发现中枢δ1和δ2阿片受体的激活均可产生奖赏效应。此外,这些结果表明,δ1阿片受体激动剂的奖赏效应可能是通过激活中枢多巴胺能系统,尤其是多巴胺D1受体产生的,而δ2阿片受体激动剂的奖赏效应可能是由其他某种机制产生的。